Trial Profile

A Phase 3, Placebo-Controlled, Double-Blind Comparative Study of KHK4827 With an Open-Label Extension in Subjects With Palmoplantar Pustulosis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 16 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Aug 2023 According to Kyowa Kirin media release, results have been presented at the Congress of European Academy of Dermatology and Venereology (EADV) in September 2022.
23 Aug 2023 According to Kyowa Kirin media release, results from this study will be presented at the Annual Meeting of the Japanese Society of Psoriasis Research in August 2023.
23 Aug 2023 According to Kyowa Kirin media release, the company has received approval from the Ministry of Health, Labour and Welfare for partial change of approved indication of LUMICEF 1[KHK4827 for the treatment of palmoplantar pustulosis.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com